Your browser doesn't support javascript.
High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris
Francois Anna; Sophie Goyard; Ana Ines Lalanne; Fabien Nevo; Marion Gransagne; Philippe Souque; Delphine Louis; Veronique Gillon; Isabelle Turbiez; Francois-Clement Bidard; Aline Gobillon; Alexia Savignoni; Maude Guillot-Delost; Francois Dejardin; Evelyne Dufour; Stephane Petres; Odile Richard-Le Goff; Zaineb Choucha; Olivier Helynck; Yves L Janin; Nicolas Escriou; Pierre Charneau; Franck Perez; Thierry ROSE; Olivier Lantz.
  • Francois Anna; Theravectys, Paris, France
  • Sophie Goyard; Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, Paris, France
  • Ana Ines Lalanne; Laboratoire d'Immunologie Clinique, Institut Curie, Paris, France.
  • Fabien Nevo; Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, France
  • Marion Gransagne; Innovation Laboratory: Vaccines, Institut Pasteur, Paris, France
  • Philippe Souque; Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, France
  • Delphine Louis; Laboratoire d'Immunologie Clinique, Institut Curie, Paris, France
  • Veronique Gillon; Direction of the Clinical Research, Institut Curie, Paris, France
  • Isabelle Turbiez; Direction of the Clinical Research, Institut Curie, 75005, France
  • Francois-Clement Bidard; Centre d'Investigation Clinique en Biotherapie, Institut Curie (CIC-BT1428), Paris, France
  • Aline Gobillon; Biometry, Institut Curie, Paris, France
  • Alexia Savignoni; Biometry, Institut Curie, Paris, France
  • Maude Guillot-Delost; Centre d'Investigation Clinique en Biotherapie, Institut Curie (CIC-BT1428), Paris, France
  • Francois Dejardin; Production and Purification of Recombinant Proteins Technological Platform, Paris, France
  • Evelyne Dufour; Production and Purification of Recombinant Proteins Technological Platform, Paris, France
  • Stephane Petres; Production and Purification of Recombinant Proteins Technological Platform, Paris, France
  • Odile Richard-Le Goff; Unit of Antibody in Therapy and Pathology, Institut Pasteur, Paris, France
  • Zaineb Choucha; Innovation Laboratory: Vaccines, Institut Pasteur, Paris, France
  • Olivier Helynck; Unit of Chemistry and Biocatalysis, Institut Pasteur, UMR 3523 CNRS, Paris, France
  • Yves L Janin; Unit of Chemistry and Biocatalysis, Institut Pasteur, UMR 3523 CNRS, Paris, France
  • Nicolas Escriou; Innovation Laboratory: Vaccines, Institut Pasteur, Paris, France
  • Pierre Charneau; Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, France
  • Franck Perez; Unit of Cell Biology and Cancer, Institut Curie
  • Thierry ROSE; Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, Paris, France
  • Olivier Lantz; Laboratoire d'Immunologie Clinique, Institut Curie, Paris, France.
Preprint in English | medRxiv | ID: ppmedrxiv-20219030
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
Although the COVID-19 pandemic peaked in March/April 2020 in France, the prevalence of infection is barely known. Herein, we assessed using high-throughput methods the serological response against the SARS-CoV-2 virus of 1847 participants working in one institution in Paris. In May-July 2020, 11% (95% CI 9.7-12.6) of serums were positive for IgG against the SARS-CoV-2 N and S proteins and 9.5% (CI8.2-11.0) were pseudo-neutralizer. The prevalence of immunization was 11.6% (CI10.2-13.2) considering positivity in at least one assays. In 5% (CI3.9-7.1) of RT-qPCR positive individuals, no systemic IgGs were detected. Among immune individuals, 21% had been asymptomatic. Anosmia and ageusia occurred in 52% of the IgG-positive individuals and in 3% of the negative ones. In contrast, 30% of the anosmia-ageusia cases were seronegative suggesting that the true prevalence of infection may reach 16.6%. In sera obtained 4-8 weeks after the first sampling anti-N and anti-S IgG titers and pseudo-neutralization activity declined by 31%, 17% and 53%, respectively with half-life of 35, 87 and 28 days, respectively. The population studied is representative of active workers in Paris. The short lifespan of the serological systemic responses suggests an underestimation the true prevalence of infection.
Full text: Available Collection: Preprints Database: medRxiv Type of study: Risk factors Language: English Year: 2020 Document Type: Preprint

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Collection: Preprints Database: medRxiv Type of study: Risk factors Language: English Year: 2020 Document Type: Preprint